Twist Bioscience ( (TWST) ) has released its Q4 earnings. Here is a breakdown of the information Twist Bioscience presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Twist Bioscience Corporation, a mid-cap biotech company, specializes in synthetic DNA tools for various sectors including medicine and agriculture, leveraging its innovative silicon-based DNA synthesis platform. The company reported a record revenue of $376.6 million for fiscal 2025, marking a 20% increase from the previous year, with significant growth across its SynBio, NGS, and Biopharma segments. The fourth quarter alone saw a 17% revenue increase to $99 million, continuing its streak of sequential growth. Key financial metrics include an improved gross margin of 50.7% for the year and a reduced net loss of $77.7 million, down from $208.7 million in fiscal 2024. The company also made strategic advancements, including launching new products and expanding its customer base. Looking ahead, Twist Bioscience anticipates continued growth with projected revenues between $425 million and $435 million for fiscal 2026, while maintaining a gross margin above 52% and achieving adjusted EBITDA breakeven by the fourth quarter.